GlassScriptPhysician profile
Brian Jones
NPI 1194236273
$3,312.32
in general payments reported to CMS, 2019-2025
30 companies · $188 in 2025
The $188 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,964 · 2022: $34.95 · 2023: $1,125 · 2025: $188.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,110 · Food and Beverage: $203.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,110.33 |
| Food and Beverage | $202.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pacira Pharmaceuticals Incorporated | $1,164.96 | 2022-2025 | Iovera, Exparel, Zilretta |
| Abbvie INC. | $421.93 | 2021 | |
| Novo Nordisk INC | $264.34 | 2021-2025 | Wegovy |
| Teva Pharmaceuticals USA, INC. | $212.75 | 2021-2025 | Uzedy |
| Pfizer INC. | $163.85 | 2021 | |
| Lilly USA, LLC | $143.16 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $124.33 | 2021 | |
| Sanofi-Aventis U.S. LLC | $96.54 | 2021 | |
| Amarin Pharma, INC. | $86.04 | 2021 | |
| Amgen INC. | $59.08 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $55.73 | 2021 | |
| Depuy Synthes Sales INC. | $55.56 | 2025 | Monovisc, Orthovisc |
| Merck Sharp & Dohme LLC | $53.19 | 2021 | |
| Janssen Pharmaceuticals, INC | $53.16 | 2021 | |
| Abbott Laboratories | $49.00 | 2021 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $47.56 | 2021 | |
| Scilex Pharmaceuticals INC. | $30.16 | 2021 | |
| Adlon Therapeutics L.P. | $27.24 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $25.23 | 2021 | |
| Allergan, INC. | $23.34 | 2021 | |
| Genentech USA, INC. | $21.28 | 2021 | |
| Biogen, INC. | $21.01 | 2021 | |
| Cumberland Pharmaceuticals, INC. | $18.08 | 2025 | Caldolor |
| Takeda Pharmaceuticals U.S.A., INC. | $17.25 | 2021 | |
| Ferring Pharmaceuticals INC. | $14.89 | 2022 | |
| Glaxosmithkline, LLC. | $13.92 | 2021 | |
| Althera Pharmaceuticals LLC | $13.46 | 2021 | |
| Leo Pharma INC. | $12.55 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $11.77 | 2021 | |
| Clarus Therapeutics INC. | $10.96 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Jones listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.